Pharmacological aspects and spectrum of action of ceftazidime–avibactam: a systematic review
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Pharmacological aspects and spectrum of action of ceftazidime–avibactam: a systematic review
Authors
Keywords
Cephalosporin, Pharmacology, Avibactam, Ceftazidime
Journal
INFECTION
Volume 46, Issue 2, Pages 165-181
Publisher
Springer Nature
Online
2017-11-07
DOI
10.1007/s15010-017-1096-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Activity of ceftazidime–avibactam against multidrug-resistance Enterobacteriaceae expressing combined mechanisms of resistance
- (2017) Inmaculada López-Hernández et al. ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA
- Impact of defined cell envelope mutations in Escherichia coli on the in vitro antibacterial activity of avibactam/β-lactam combinations
- (2017) Sarah M. McLeod et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Treating complicated carbapenem-resistant enterobacteriaceae infections with ceftazidime/avibactam: a retrospective study with molecular strain characterisation
- (2017) Fiorella Krapp et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Clinical efficacy of ceftazidime/avibactam versus other active agents for the treatment of bacteremia due to carbapenemase-producing Enterobacteriaceae in hematologic patients
- (2017) Juan J. Castón et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- Comparison of antimicrobial activity between ceftolozane–tazobactam and ceftazidime–avibactam against multidrug-resistant isolates of Escherichia coli , Klebsiella pneumoniae , and Pseudomonas aeruginosa
- (2017) Adnan Alatoom et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- Emergence of ceftazidime/avibactam non-susceptibility in an MDR Klebsiella pneumoniae isolate
- (2017) Anna Both et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- High ceftazidime hydrolysis activity and porin OmpK35 deficiency contribute to the decreased susceptibility to ceftazidime/avibactam in KPC-producing Klebsiella pneumoniae
- (2017) Zhen Shen et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Phase I Study Assessing the Pharmacokinetic Profile, Safety, and Tolerability of a Single Dose of Ceftazidime-Avibactam in Hospitalized Pediatric Patients
- (2016) John S. Bradley et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In VitroActivity of Ceftazidime-Avibactam against Contemporary Pseudomonas aeruginosa Isolates from U.S. Medical Centers by Census Region, 2014
- (2016) Michael D. Huband et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Evaluation of theIn VitroActivity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Meropenem-Resistant Pseudomonas aeruginosa Isolates
- (2016) Deanna J. Buehrle et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Activity of Ceftazidime-Avibactam against Extended-Spectrum- and AmpC β-Lactamase-Producing Enterobacteriaceae Collected in the INFORM Global Surveillance Study from 2012 to 2014
- (2016) James A. Karlowsky et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In VitroSusceptibility to Ceftazidime-Avibactam of Carbapenem-Nonsusceptible Enterobacteriaceae Isolates Collected during the INFORM Global Surveillance Study (2012 to 2014)
- (2016) Boudewijn L. M. de Jonge et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Interaction of Avibactam with Class B Metallo-β-Lactamases
- (2016) Martine I. Abboud et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Ceftazidime-avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial Program
- (2016) Florian M. Wagenlehner et al. CLINICAL INFECTIOUS DISEASES
- High Rates of Nonsusceptibility to Ceftazidime-avibactam and Identification of New Delhi Metallo-β-lactamase Production inEnterobacteriaceaeBloodstream Infections at a Major Cancer Center: Table 1.
- (2016) Samuel L. Aitken et al. CLINICAL INFECTIOUS DISEASES
- Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program
- (2016) John E. Mazuski et al. CLINICAL INFECTIOUS DISEASES
- Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections: Table 1.
- (2016) Ryan K. Shields et al. CLINICAL INFECTIOUS DISEASES
- Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation β-Lactam/β-Lactamase Inhibitor Combinations
- (2016) David van Duin et al. CLINICAL INFECTIOUS DISEASES
- In vitro activity of ceftazidime/avibactam against Gram-negative pathogens isolated from pneumonia in hospitalised patients, including ventilated patients
- (2016) Robert K. Flamm et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Structural and sequence analysis of class A β-lactamases with respect to avibactam inhibition: impact of Ω-loop variations
- (2016) Sushmita D. Lahiri et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Phase 1 Study Assessing the Pharmacokinetic Profile and Safety of Avibactam in Patients With Renal Impairment
- (2016) Henri Merdjan et al. JOURNAL OF CLINICAL PHARMACOLOGY
- The postantibiotic effect and post-β-lactamase-inhibitor effect of ceftazidime, ceftaroline and aztreonam in combination with avibactam against target Gram-negative bacteria
- (2016) C.M. Pillar et al. LETTERS IN APPLIED MICROBIOLOGY
- Investigations on recyclisation and hydrolysis in avibactam mediated serine β-lactamase inhibition
- (2016) Hwanho Choi et al. ORGANIC & BIOMOLECULAR CHEMISTRY
- Pharmacokinetics of Ceftazidime-Avibactam in Two Patients With KPC-ProducingKlebsiella pneumoniaeBacteremia and Renal Impairment
- (2016) John J. Veillette et al. PHARMACOTHERAPY
- Ceftazidime-Avibactam Activity against Aerobic Gram Negative Organisms Isolated from Intra-Abdominal Infections in United States Hospitals, 2012–2014
- (2016) Helio S. Sader et al. Surgical Infections
- Validation of Sensititre Dry-Form Broth Microdilution Panels for Susceptibility Testing of Ceftazidime-Avibactam, a Broad-Spectrum-β-Lactamase Inhibitor Combination
- (2015) Ronald N. Jones et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Pharmacokinetics and Penetration of Ceftazidime and Avibactam into Epithelial Lining Fluid in Thigh- and Lung-Infected Mice
- (2015) Johanna Berkhout et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In VitroActivity of Ceftazidime-Avibactam against 338 Molecularly Characterized Gentamicin-Nonsusceptible Gram-Negative Clinical Isolates Obtained from Patients in Canadian Hospitals
- (2015) Andrew J. Denisuik et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Avibactam and Inhibitor-Resistant SHV β-Lactamases
- (2015) Marisa L. Winkler et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- First Report of Ceftazidime-Avibactam Resistance in a KPC-3-Expressing Klebsiella pneumoniae Isolate
- (2015) Romney M. Humphries et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Variants of β-Lactamase KPC-2 That Are Resistant to Inhibition by Avibactam
- (2015) Krisztina M. Papp-Wallace et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Pharmacodynamics of Ceftazidime and Avibactam in Neutropenic Mice with Thigh or Lung Infection
- (2015) Johanna Berkhout et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Distinctive Binding of Avibactam to Penicillin-Binding Proteins of Gram-Negative and Gram-Positive Bacteria
- (2015) Abdelhamid Asli et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In VitroAntibacterial Activity of the Ceftazidime-Avibactam Combination against Enterobacteriaceae, Including Strains with Well-Characterized β-Lactamases
- (2015) Premavathy Levasseur et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Ceftazidime-Avibactam Activity against Multidrug-Resistant Pseudomonas aeruginosa Isolated in U.S. Medical Centers in 2012 and 2013
- (2015) Helio S. Sader et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In VitroActivities of Ceftazidime-Avibactam, Aztreonam-Avibactam, and a Panel of Older and Contemporary Antimicrobial Agents against Carbapenemase-Producing Gram-Negative Bacilli
- (2015) Shawn Vasoo et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Molecular Characterization of Carbapenem-Nonsusceptible Enterobacterial Isolates Collected during a Prospective Interregional Survey in France and Susceptibility to the Novel Ceftazidime-Avibactam and Aztreonam-Avibactam Combinations
- (2015) Hervé Dupont et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Role of the Outer Membrane and Porins in Susceptibility of β-Lactamase-Producing Enterobacteriaceae to Ceftazidime-Avibactam
- (2015) Jean-Marie Pagès et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Activity of Ceftazidime-Avibactam against Fluoroquinolone-Resistant Enterobacteriaceae and Pseudomonas aeruginosa
- (2015) C. Pitart et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In VitroSelection of Ceftazidime-Avibactam Resistance in Enterobacteriaceae with KPC-3 Carbapenemase
- (2015) David M. Livermore et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Safety and Pharmacokinetics of Single and Multiple Ascending Doses of Avibactam Alone and in Combination with Ceftazidime in Healthy Male Volunteers: Results of Two Randomized, Placebo-Controlled Studies
- (2015) Henri Merdjan et al. CLINICAL DRUG INVESTIGATION
- Effect of Age and Sex on the Pharmacokinetics and Safety of Avibactam in Healthy Volunteers
- (2015) Antoine Tarral et al. CLINICAL THERAPEUTICS
- Activities of ceftazidime, ceftaroline, and aztreonam alone and combined with avibactam against isogenic Escherichia coli strains expressing selected single β-lactamases
- (2015) Krisztina M. Papp-Wallace et al. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
- Post-hemodialysis dosing of 1 vs. 2 g of ceftazidime in anuric end-stage renal disease patients on low-flux dialysis and its pharmacodynamic implications on clinical use
- (2015) Jessica Hui Fen Goh et al. Hemodialysis International
- Ecological effect of ceftazidime/avibactam on the normal human intestinal microbiota
- (2015) Mamun-Ur Rashid et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Ceftazidime/avibactam tested against Gram-negative bacteria from intensive care unit (ICU) and non-ICU patients, including those with ventilator-associated pneumonia
- (2015) Helio S. Sader et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- In vitro activity of ceftazidime, ceftaroline and aztreonam alone and in combination with avibactam against European Gram-negative and Gram-positive clinical isolates
- (2015) Raymond Testa et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Molecular characterization of MRSA isolates bracketing the current EUCAST ceftaroline-susceptible breakpoint forStaphylococcus aureus: the role of PBP2a in the activity of ceftaroline
- (2015) Sushmita D. Lahiri et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Avibactam confers susceptibility to a large proportion of ceftazidime-resistantPseudomonas aeruginosaisolates recovered from cystic fibrosis patients
- (2015) Hussein Chalhoub et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Phase 1 study assessing the steady-state concentration of ceftazidime and avibactam in plasma and epithelial lining fluid following two dosing regimens
- (2015) David P. Nicolau et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Characterization ofEscherichia coliNDM isolates with decreased susceptibility to aztreonam/avibactam: role of a novel insertion in PBP3
- (2015) Richard A. Alm et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- In vitro susceptibility of characterized β-lactamase-producing Gram-negative bacteria isolated in Japan to ceftazidime-, ceftaroline-, and aztreonam-avibactam combinations
- (2015) Ayumi Yoshizumi et al. JOURNAL OF INFECTION AND CHEMOTHERAPY
- Inhibition of Klebsiella β-Lactamases (SHV-1 and KPC-2) by Avibactam: A Structural Study
- (2015) Nikhil P. Krishnan et al. PLoS One
- Molecular Basis of Selective Inhibition and Slow Reversibility of Avibactam against Class D Carbapenemases: A Structure-Guided Study of OXA-24 and OXA-48
- (2014) Sushmita D. Lahiri et al. ACS Chemical Biology
- In VivoEfficacy of Humanized Exposures of Ceftazidime-Avibactam in Comparison with Ceftazidime against Contemporary Enterobacteriaceae Isolates
- (2014) Shawn H. MacVane et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In VitroSusceptibility of Characterized β-Lactamase-Producing Strains Tested with Avibactam Combinations
- (2014) Henry Li et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In Vitro Activity of Plazomicin against 5,015 Gram-Negative and Gram-Positive Clinical Isolates Obtained from Patients in Canadian Hospitals as Part of the CANWARD Study, 2011-2012
- (2014) A. Walkty et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- UnexpectedIn VivoActivity of Ceftazidime Alone and in Combination with Avibactam against New Delhi Metallo-β-Lactamase-Producing Enterobacteriaceae in a Murine Thigh Infection Model
- (2014) Shawn H. MacVane et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Reclaiming the Efficacy of β-Lactam–β-Lactamase Inhibitor Combinations: Avibactam Restores the Susceptibility of CMY-2-Producing Escherichia coli to Ceftazidime
- (2014) Krisztina M. Papp-Wallace et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Avibactam and Class C β-Lactamases: Mechanism of Inhibition, Conservation of the Binding Pocket, and Implications for Resistance
- (2014) S. D. Lahiri et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Bactericidal Activity, Absence of Serum Effect, and Time-Kill Kinetics of Ceftazidime-Avibactam against β-Lactamase-Producing Enterobacteriaceae and Pseudomonas aeruginosa
- (2014) Tiffany R. Keepers et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In VitroActivity of Ceftazidime-Avibactam Combination inIn VitroCheckerboard Assays
- (2014) Johanna Berkhout et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Unexpected Challenges in Treating Multidrug-Resistant Gram-Negative Bacteria: Resistance to Ceftazidime-Avibactam in Archived Isolates of Pseudomonas aeruginosa
- (2014) Marisa L. Winkler et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Activities of Ceftazidime and Avibactam against β-Lactamase-Producing Enterobacteriaceae in a Hollow-Fiber Pharmacodynamic Model
- (2014) Ken Coleman et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Inactivation of TEM-1 by Avibactam (NXL-104): Insights from Quantum Mechanics/Molecular Mechanics Metadynamics Simulations
- (2014) Jacopo Sgrignani et al. BIOCHEMISTRY
- Ceftazidime-avibactam and comparator agents tested against urinary tract isolates from a global surveillance program (2011)
- (2014) Robert K. Flamm et al. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
- Microbiological interaction studies between ceftazidime-avibactam and pulmonary surfactant and between ceftazidime-avibactam and antibacterial agents of other classes
- (2014) John Dallow et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Kinetics of the interaction between avibactam and the CHE-1 class C -lactamase
- (2014) A. Fernea et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Activity of avibactam against Enterobacter cloacae producing an extended-spectrum class C -lactamase enzyme
- (2014) S. D. Lahiri et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Avibactam activity against extended-spectrum AmpC -lactamases
- (2014) N. Porres-Osante et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Ceftazidime/avibactam activity tested against Gram-negative bacteria isolated from bloodstream, pneumonia, intra-abdominal and urinary tract infections in US medical centres (2012)
- (2014) R. K. Flamm et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Human Simulated Studies of Aztreonam and Aztreonam-Avibactam To Evaluate Activity against Challenging Gram-Negative Organisms, Including Metallo-β-Lactamase Producers
- (2013) Jared L. Crandon et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Efficacies of Ceftazidime-Avibactam and Ceftazidime against Pseudomonas aeruginosa in a Murine Lung Infection Model
- (2013) Seth T. Housman et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Structural Insight into Potent Broad-Spectrum Inhibition with Reversible Recyclization Mechanism: Avibactam in Complex with CTX-M-15 and Pseudomonas aeruginosa AmpC β-Lactamases
- (2013) Sushmita D. Lahiri et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Contemporary Diversity of β-Lactamases among Enterobacteriaceae in the Nine U.S. Census Regions and Ceftazidime-Avibactam Activity Tested against Isolates Producing the Most Prevalent β-Lactamase Groups
- (2013) Mariana Castanheira et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Antimicrobial Activity of Ceftazidime-Avibactam against Gram-Negative Organisms Collected from U.S. Medical Centers in 2012
- (2013) Helio S. Sader et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Comparative in vitro activity of ceftaroline, ceftaroline-avibactam, and other antimicrobial agents against aerobic and anaerobic bacteria cultured from infected diabetic foot wounds
- (2013) Ellie J.C. Goldstein et al. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
- Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, Phase II trial
- (2013) Christopher Lucasti et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Kinetics of Avibactam Inhibition against Class A, C, and D β-Lactamases
- (2013) David E. Ehmann et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- The β-lactamase inhibitor avibactam (NXL104) does not induce ampC β -lactamase in Enterobacter cloacae
- (2013) Christine Miossec et al. Infection and Drug Resistance
- Treatment Outcome of Bacteremia Due to KPC-Producing Klebsiella pneumoniae: Superiority of Combination Antimicrobial Regimens
- (2012) Zubair A. Qureshi et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- ComparativeIn VitroandIn VivoEfficacies of Human Simulated Doses of Ceftazidime and Ceftazidime-Avibactam against Pseudomonas aeruginosa
- (2012) Jared L. Crandon et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In VitroAntibacterial Activity of the Ceftazidime-Avibactam (NXL104) Combination against Pseudomonas aeruginosa Clinical Isolates
- (2012) Premavathy Levasseur et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Emergence of Klebsiella pneumoniae-producing KPC-2 carbapenemase in Paraíba, Northeastern Brazil
- (2012) Lorena C.C. Fehlberg et al. Brazilian Journal of Infectious Diseases
- Efficacy and safety of ceftazidime–avibactam versus imipenem–cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study
- (2012) José A. Vazquez et al. CURRENT MEDICAL RESEARCH AND OPINION
- Antimicrobial resistance among Gram-negative bacilli isolated from Latin America: results from SENTRY Antimicrobial Surveillance Program (Latin America, 2008–2010)
- (2012) Ana C. Gales et al. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
- Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole
- (2012) L.J. Dubreuil et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Avibactam is a covalent, reversible, non- -lactam -lactamase inhibitor
- (2012) D. E. Ehmann et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Multidrug resistance genes, including blaKPC and blaCTX-M-2, among Klebsiella pneumoniae isolated in Recife, Brazil
- (2012) Adriane Borges Cabral et al. Revista da Sociedade Brasileira de Medicina Tropical
- In VitroActivity of Ceftazidime-NXL104 against 396 Strains of β-Lactamase-Producing Anaerobes
- (2011) Diane M. Citron et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In VivoEfficacy of a Human-Simulated Regimen of Ceftaroline Combined with NXL104 against Extended-Spectrum-β-Lactamase (ESBL)-Producing and Non-ESBL-Producing Enterobacteriaceae
- (2011) Dora E. Wiskirchen et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- The Challenges of Antimicrobial Resistance in Brazil
- (2011) F. Rossi CLINICAL INFECTIOUS DISEASES
- Activity of a novel combination against multidrug-resistant nonfermenters: ceftazidime plus NXL104
- (2011) Daniel Curcio Expert Review of Anti-Infective Therapy
- In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae
- (2011) Z. Aktaş et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Molecular Epidemiology, Sequence Types, and Plasmid Analyses of KPC-Producing Klebsiella pneumoniae Strains in Israel
- (2010) A. Leavitt et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Mechanistic Studies of the Inactivation of TEM-1 and P99 by NXL104, a Novel Non- -Lactam -Lactamase Inhibitor
- (2010) T. Stachyra et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Genetic Factors Associated with Elevated Carbapenem Resistance in KPC-Producing Klebsiella pneumoniae
- (2010) B. Kitchel et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Evaluation of Ceftazidime and NXL104 in Two Murine Models of Infection Due to KPC-ProducingKlebsiella pneumoniae
- (2010) Andrea Endimiani et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Three Decades of -Lactamase Inhibitors
- (2010) S. M. Drawz et al. CLINICAL MICROBIOLOGY REVIEWS
- Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant Enterobacteriaceae isolates
- (2010) D. M. Livermore et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Activity of chequerboard combinations of ceftaroline and NXL104 versus -lactamase-producing Enterobacteriaceae
- (2010) S. Mushtaq et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- In vitro activity of ceftazidime+NXL104 against Pseudomonas aeruginosa and other non-fermenters
- (2010) S. Mushtaq et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Early Dissemination of KPC-2-Producing Klebsiella pneumoniae Strains in Brazil
- (2009) M. Pavez et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In Vitro Activity of NXL104 in Combination with -Lactams against Klebsiella pneumoniae Isolates Producing KPC Carbapenemases
- (2009) A. Endimiani et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In vitro activity of the -lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemases
- (2009) T. Stachyra et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria
- (2009) Patrice Nordmann et al. LANCET INFECTIOUS DISEASES
- Genetic Structures at the Origin of Acquisition of the -Lactamase blaKPC Gene
- (2008) T. Naas et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Carbapenem-hydrolysing -lactamase KPC-2 in Klebsiella pneumoniae isolated in Rio de Janeiro, Brazil
- (2008) G. Peirano et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Arrival of Klebsiella pneumoniae producing KPC carbapenemase in the United Kingdom
- (2008) N. Woodford et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- NXL104 combinations versus Enterobacteriaceae with CTX-M extended-spectrum -lactamases and carbapenemases
- (2008) D. M. Livermore et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now